These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 6648155)
21. Strategies for designing clinical trials for oligonucleotide therapeutics. Wacheck V Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726 [TBL] [Abstract][Full Text] [Related]
22. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials. Rodgers A; MacMahon S Thromb Haemost; 1995 Feb; 73(2):167-71. PubMed ID: 7792725 [TBL] [Abstract][Full Text] [Related]
26. [Assessment of the course of a disease in the therapeutic comparison]. Horbach L Arzneimittelforschung; 1974 Jul; 24(7):1001-4. PubMed ID: 4408031 [No Abstract] [Full Text] [Related]
27. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Gritz ER; Dresler C; Sarna L Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2287-93. PubMed ID: 16214906 [TBL] [Abstract][Full Text] [Related]
28. An updated catalog of prostate cancer predictive tools. Shariat SF; Karakiewicz PI; Roehrborn CG; Kattan MW Cancer; 2008 Dec; 113(11):3075-99. PubMed ID: 18823041 [TBL] [Abstract][Full Text] [Related]
29. Clinical trial strategies and future challenges in the investigation of human congestive heart failure. Leier CV Pharmacotherapy; 1993; 13(5 Pt 2):94S-99S. PubMed ID: 8233998 [TBL] [Abstract][Full Text] [Related]
30. Proceedings of the Workshop on Evaluation of Therapy. September 1983. Bethesda, MD. Stat Med; 1984; 3(4):305-478. PubMed ID: 6528129 [No Abstract] [Full Text] [Related]
31. The role of prognostic stratification in preventing the bias permitted by random allocation of treatment. Feinstein AR; Landis JR J Chronic Dis; 1976 Apr; 29(4):277-84. PubMed ID: 773948 [No Abstract] [Full Text] [Related]
32. The need for randomization in the study of intended effects. Miettinen OS Stat Med; 1983; 2(2):267-71. PubMed ID: 6648141 [TBL] [Abstract][Full Text] [Related]
33. Hypothesis testing of time-dependent recurrent events. Stukel TA Stat Med; 1989 Apr; 8(4):517-9. PubMed ID: 2727472 [No Abstract] [Full Text] [Related]
35. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
36. [Demonstration of a similarity of effect among several therapies: technics and value in medical decision-making]. Lacaine F; Rodary C; Flamant R Gastroenterol Clin Biol; 1981; 5(6-7):599-603. PubMed ID: 7250612 [No Abstract] [Full Text] [Related]
37. Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials. Haybittle J Stat Med; 1983; 2(3):415-6. PubMed ID: 6648155 [No Abstract] [Full Text] [Related]
38. [Evaluation of medical practices]. Battista RN Union Med Can; 1980 Oct; 109(10):1462-7. PubMed ID: 6781111 [No Abstract] [Full Text] [Related]